Terms: = Brain cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
1430 results:
1. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
2. Rathke's Cleft Cyst and Craniopharyngioma: A Continuum of the Same Spectrum? Insights from an Interesting Case and Previous Literature.
Sharma R; Meena R; Ganeshkumar A; Narwal A; Doddamani R; Singh M; Chandra SP
Neurol India; 2024 Mar; 72(2):403-407. PubMed ID: 38691485
[TBL] [Abstract] [Full Text] [Related]
3. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
4. braf and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract] [Full Text] [Related]
5. Relevance of mutations in protein deubiquitinases genes and
Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
[TBL] [Abstract] [Full Text] [Related]
6. Anti-PD-(L)1 plus braf/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of
Ramakrishnan D; Brüningk SC; von Reppert M; Memon F; Maleki N; Aneja S; Kazerooni AF; Nabavizadeh A; Lin M; Bousabarah K; Molinaro A; Nicolaides T; Prados M; Mueller S; Aboian MS
AJNR Am J Neuroradiol; 2024 Apr; 45(4):475-482. PubMed ID: 38453411
[TBL] [Abstract] [Full Text] [Related]
9. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning.
Tak D; Ye Z; Zapaischykova A; Zha Y; Boyd A; Vajapeyam S; Chopra R; Hayat H; Prabhu SP; Liu KX; Elhalawani H; Nabavizadeh A; Familiar A; Resnick AC; Mueller S; Aerts HJWL; Bandopadhayay P; Ligon KL; Haas-Kogan DA; Poussaint TY; Kann BH
Radiol Artif Intell; 2024 May; 6(3):e230333. PubMed ID: 38446044
[TBL] [Abstract] [Full Text] [Related]
10. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.
Vedovatto S; Oliveira FD; Pereira LC; Scheffel TB; Beckenkamp LR; Bertoni APS; Wink MR; Lenz G
Cell Commun Signal; 2024 Feb; 22(1):145. PubMed ID: 38388432
[TBL] [Abstract] [Full Text] [Related]
11. MET receptor serves as a promising target in melanoma brain metastases.
Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
Acta Neuropathol; 2024 Feb; 147(1):44. PubMed ID: 38386085
[TBL] [Abstract] [Full Text] [Related]
12. Promising response to vemurafenib and cobimetinib treatment for braf V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract] [Full Text] [Related]
13. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
Li J; Shih LK; Brat DJ
Cancer Res; 2024 May; 84(9):1379-1381. PubMed ID: 38330148
[TBL] [Abstract] [Full Text] [Related]
14. Clinical and molecular study of radiation-induced gliomas.
Trkova K; Sumerauer D; Bubenikova A; Krskova L; Vicha A; Koblizek M; Zamecnik J; Jurasek B; Kyncl M; Malinova B; Ondrova B; Jones DTW; Sill M; Strnadova M; Stolova L; Misove A; Benes V; Zapotocky M
Sci Rep; 2024 Feb; 14(1):3118. PubMed ID: 38326438
[TBL] [Abstract] [Full Text] [Related]
15. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
Gritsch D; Santagata S; Brastianos PK
Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
[TBL] [Abstract] [Full Text] [Related]
16. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract] [Full Text] [Related]
17. Mosaic RASopathies concept: different skin lesions, same systemic manifestations?
Morren MA; Fodstad H; Brems H; Bedoni N; Guenova E; Jacot-Guillarmod M; Busiah K; Giuliano F; Gilliet M; Atallah I
J Med Genet; 2024 Apr; 61(5):411-419. PubMed ID: 38290824
[TBL] [Abstract] [Full Text] [Related]
18. [Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].
Morimoto A; Sakamoto K; Kudo K; Shioda Y
Rinsho Shinkeigaku; 2024 Feb; 64(2):85-92. PubMed ID: 38281751
[TBL] [Abstract] [Full Text] [Related]
19. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
Papadopoulou E; Rigas G; Fountzilas E; Boutis A; Giassas S; Mitsimponas N; Daliani D; Ziogas DC; Liontos M; Ramfidis V; Christophilakis C; Matthaios D; Floros T; Florou-Chatzigiannidou C; Agiannitopoulos K; Meintani A; Tsantikidi A; Katseli A; Potska K; Tsaousis G; Metaxa-Mariatou V; Nasioulas G
JCO Precis Oncol; 2024 Jan; 8():e2300332. PubMed ID: 38271656
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptional features of low-grade neuroepithelial tumors with the braf V600E mutation associated with epileptogenicity.
Iijima K; Komatsu K; Miyashita S; Suyama K; Murayama K; Hashizume K; Tabe NK; Miyata H; Iwasaki M; Taya S; Hoshino M
Genes Cells; 2024 Mar; 29(3):192-206. PubMed ID: 38269481
[TBL] [Abstract] [Full Text] [Related]
[Next]
